UA73988C2 - SOLID BODY FORMS OF MESOPROGESTIN -11b-[4??-(HYDROXY IMINOMETHYL)-PHENYL]-17a-METHOXY-17b-METHOXY-ESTRA-4,9-DIEN-3-ONE - Google Patents

SOLID BODY FORMS OF MESOPROGESTIN -11b-[4??-(HYDROXY IMINOMETHYL)-PHENYL]-17a-METHOXY-17b-METHOXY-ESTRA-4,9-DIEN-3-ONE Download PDF

Info

Publication number: UA73988C2
Authority: UA; Ukraine
Prior art keywords: solvate; dien; phenyl; hydroxyiminomethyl; methoxymethyl
Prior art date: 2000-05-23

Application number

UA20021210147A

Other languages

English (en)

Ukrainian (uk)

Original Assignee

Schering Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-05-23

Filing date

2001-09-05

Publication date

2005-10-17

2001-09-05 Application filed by Schering Ag filed Critical Schering Ag

2005-10-17 Publication of UA73988C2 publication Critical patent/UA73988C2/uk

Links

239000007787 solid Substances 0.000 title abstract description 12
238000000034 method Methods 0.000 claims abstract description 19
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 6
238000002657 hormone replacement therapy Methods 0.000 claims abstract description 3
239000012453 solvate Substances 0.000 claims description 72
BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims description 31
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 27
239000002904 solvent Substances 0.000 claims description 21
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 18
238000001035 drying Methods 0.000 claims description 16
239000000126 substance Substances 0.000 claims description 11
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 10
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
239000003814 drug Substances 0.000 claims description 9
238000001953 recrystallisation Methods 0.000 claims description 9
238000010438 heat treatment Methods 0.000 claims description 8
238000000634 powder X-ray diffraction Methods 0.000 claims description 8
238000004807 desolvation Methods 0.000 claims description 6
230000008569 process Effects 0.000 claims description 6
230000009477 glass transition Effects 0.000 claims description 5
239000000843 powder Substances 0.000 claims description 5
238000001694 spray drying Methods 0.000 claims description 5
229940124597 therapeutic agent Drugs 0.000 claims description 5
238000002425 crystallisation Methods 0.000 claims description 4
230000008025 crystallization Effects 0.000 claims description 4
238000002329 infrared spectrum Methods 0.000 claims description 4
238000005507 spraying Methods 0.000 claims description 4
239000003085 diluting agent Substances 0.000 claims description 3
239000003112 inhibitor Substances 0.000 claims description 3
229940126601 medicinal product Drugs 0.000 claims description 3
230000001419 dependent effect Effects 0.000 claims description 2
238000004090 dissolution Methods 0.000 claims description 2
239000003937 drug carrier Substances 0.000 claims description 2
239000005556 hormone Substances 0.000 claims description 2
229940088597 hormone Drugs 0.000 claims description 2
-1 E-(hydroxyiminomethyl)phenyl Chemical group 0.000 claims 2
230000001850 reproductive effect Effects 0.000 claims 1
150000002923 oximes Chemical class 0.000 abstract description 33
150000001875 compounds Chemical class 0.000 abstract description 8
230000001747 exhibiting effect Effects 0.000 abstract 1
230000035558 fertility Effects 0.000 abstract 1
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 21
239000000243 solution Substances 0.000 description 13
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical group CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 7
230000000694 effects Effects 0.000 description 5
229910052757 nitrogen Inorganic materials 0.000 description 5
239000000047 product Substances 0.000 description 5
239000013543 active substance Substances 0.000 description 4
238000000113 differential scanning calorimetry Methods 0.000 description 4
238000012545 processing Methods 0.000 description 4
230000009466 transformation Effects 0.000 description 4
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
206010027514 Metrorrhagia Diseases 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
208000035475 disorder Diseases 0.000 description 3
239000007789 gas Substances 0.000 description 3
239000013067 intermediate product Substances 0.000 description 3
238000006317 isomerization reaction Methods 0.000 description 3
238000002844 melting Methods 0.000 description 3
230000008018 melting Effects 0.000 description 3
102000003998 progesterone receptors Human genes 0.000 description 3
108090000468 progesterone receptors Proteins 0.000 description 3
239000004094 surface-active agent Substances 0.000 description 3
FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
208000005171 Dysmenorrhea Diseases 0.000 description 2
206010013935 Dysmenorrhoea Diseases 0.000 description 2
206010034650 Peritoneal adhesions Diseases 0.000 description 2
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
239000003418 antiprogestin Substances 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
238000004440 column chromatography Methods 0.000 description 2
239000000306 component Substances 0.000 description 2
238000002050 diffraction method Methods 0.000 description 2
229940011871 estrogen Drugs 0.000 description 2
239000000262 estrogen Substances 0.000 description 2
230000003054 hormonal effect Effects 0.000 description 2
239000012535 impurity Substances 0.000 description 2
239000000463 material Substances 0.000 description 2
208000007106 menorrhagia Diseases 0.000 description 2
239000000203 mixture Substances 0.000 description 2
239000002245 particle Substances 0.000 description 2
239000012071 phase Substances 0.000 description 2
230000002980 postoperative effect Effects 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
230000002265 prevention Effects 0.000 description 2
238000000746 purification Methods 0.000 description 2
230000011514 reflex Effects 0.000 description 2
238000000926 separation method Methods 0.000 description 2
235000019333 sodium laurylsulphate Nutrition 0.000 description 2
239000007921 spray Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
206010013908 Dysfunctional uterine bleeding Diseases 0.000 description 1
201000009273 Endometriosis Diseases 0.000 description 1
208000032843 Hemorrhage Diseases 0.000 description 1
238000004566 IR spectroscopy Methods 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
WXOMTJVVIMOXJL-BOBFKVMVSA-A O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)OS(=O)(=O)OC[C@H]1O[C@@H](O[C@]2(COS(=O)(=O)O[Al](O)O)O[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]2OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]1OS(=O)(=O)O[Al](O)O Chemical compound O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)OS(=O)(=O)OC[C@H]1O[C@@H](O[C@]2(COS(=O)(=O)O[Al](O)O)O[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]2OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]1OS(=O)(=O)O[Al](O)O WXOMTJVVIMOXJL-BOBFKVMVSA-A 0.000 description 1
229910003986 SicO Inorganic materials 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
206010046798 Uterine leiomyoma Diseases 0.000 description 1
WAHQVRCNDCHDIB-QZYSPNBYSA-N [(3s,8r,9s,10r,13s,14s,17r)-17-acetyl-17-acetyloxy-6,10,13-trimethyl-1,2,3,8,9,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-yl] 3-cyclopentylpropanoate Chemical compound O([C@@H]1C=C2C(C)=C[C@H]3[C@@H]4CC[C@]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)(OC(=O)C)C(C)=O)C(=O)CCC1CCCC1 WAHQVRCNDCHDIB-QZYSPNBYSA-N 0.000 description 1
230000001270 agonistic effect Effects 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
230000003042 antagnostic effect Effects 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
230000008901 benefit Effects 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
238000009835 boiling Methods 0.000 description 1
239000006227 byproduct Substances 0.000 description 1
239000000969 carrier Substances 0.000 description 1
238000002144 chemical decomposition reaction Methods 0.000 description 1
238000004140 cleaning Methods 0.000 description 1
239000013078 crystal Substances 0.000 description 1
238000001514 detection method Methods 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
230000004064 dysfunction Effects 0.000 description 1
239000003480 eluent Substances 0.000 description 1
238000010828 elution Methods 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000012467 final product Substances 0.000 description 1
239000010419 fine particle Substances 0.000 description 1
125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 1
230000004927 fusion Effects 0.000 description 1
238000004817 gas chromatography Methods 0.000 description 1
229910052732 germanium Inorganic materials 0.000 description 1
GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 1
230000003179 granulation Effects 0.000 description 1
238000005469 granulation Methods 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
201000010260 leiomyoma Diseases 0.000 description 1
239000007788 liquid Substances 0.000 description 1
230000007774 longterm Effects 0.000 description 1
238000005259 measurement Methods 0.000 description 1
238000000691 measurement method Methods 0.000 description 1
238000002454 metastable transfer emission spectrometry Methods 0.000 description 1
229960003248 mifepristone Drugs 0.000 description 1
VKHAHZOOUSRJNA-GCNJZUOMSA-N mifepristone Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=CC=C(N(C)C)C=C1 VKHAHZOOUSRJNA-GCNJZUOMSA-N 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
239000012299 nitrogen atmosphere Substances 0.000 description 1
238000010606 normalization Methods 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
238000006146 oximation reaction Methods 0.000 description 1
239000005426 pharmaceutical component Substances 0.000 description 1
239000011148 porous material Substances 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
239000000583 progesterone congener Substances 0.000 description 1
HHAVHBDPWSUKHZ-UHFFFAOYSA-N propan-2-ol;propan-2-one Chemical compound CC(C)O.CC(C)=O HHAVHBDPWSUKHZ-UHFFFAOYSA-N 0.000 description 1
238000003908 quality control method Methods 0.000 description 1
230000005855 radiation Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
239000013557 residual solvent Substances 0.000 description 1
238000005070 sampling Methods 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
238000004611 spectroscopical analysis Methods 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
238000013112 stability test Methods 0.000 description 1
239000007858 starting material Substances 0.000 description 1
238000003756 stirring Methods 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000000844 transformation Methods 0.000 description 1
CPUDPFPXCZDNGI-UHFFFAOYSA-N triethoxy(methyl)silane Chemical compound CCO[Si](C)(OCC)OCC CPUDPFPXCZDNGI-UHFFFAOYSA-N 0.000 description 1
239000012808 vapor phase Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/36—Antigestagens
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0077—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom
- C07J41/0083—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom substituted in position 11-beta by an optionally substituted phenyl group not further condensed with other rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Reproductive Health (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Endocrinology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Gynecology & Obstetrics (AREA)
Pregnancy & Childbirth (AREA)
Diabetes (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Steroid Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

UA20021210147A 2000-05-23 2001-09-05 SOLID BODY FORMS OF MESOPROGESTIN -11b-[4??-(HYDROXY IMINOMETHYL)-PHENYL]-17a-METHOXY-17b-METHOXY-ESTRA-4,9-DIEN-3-ONE UA73988C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP00110887A EP1157996A1 (de)	2000-05-23	2000-05-23	Neue Festkörperformen des Mesoprogestins 11Beta-[4E-(Hydroxyiminomethyl)-phenyl]-17Alpha-methoxymethyl-17Beta-methoxy-estra-4,9-dien-3-on
PCT/EP2001/005237 WO2001090137A2 (de)	2000-05-23	2001-05-09	NEUE FESTKÖRPERFORMEN DES MESOPROGESTINS 11β-[4E-(HYDROXYIMINOMETHYL)-PHENYL]-17α-METHOXYMETHYL-17β-METHOXY-ESTRA-4,9-DIEN-3-ON

Publications (1)

Publication Number	Publication Date
UA73988C2 true UA73988C2 (en)	2005-10-17

Family

ID=8168805

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA20021210147A UA73988C2 (en)	2000-05-23	2001-09-05	SOLID BODY FORMS OF MESOPROGESTIN -11b-[4??-(HYDROXY IMINOMETHYL)-PHENYL]-17a-METHOXY-17b-METHOXY-ESTRA-4,9-DIEN-3-ONE

Country Status (30)

Country	Link
US (1)	US7799770B2 (pt)
EP (3)	EP1157996A1 (pt)
JP (1)	JP2003534350A (pt)
KR (1)	KR100553292B1 (pt)
CN (1)	CN100384867C (pt)
AT (1)	ATE397617T1 (pt)
AU (2)	AU2001256344B2 (pt)
BG (1)	BG65968B1 (pt)
BR (1)	BR0111058A (pt)
CA (1)	CA2409869C (pt)
CZ (1)	CZ2003620A3 (pt)
DE (1)	DE50114012D1 (pt)
DK (1)	DK1292607T3 (pt)
EA (1)	EA005623B1 (pt)
EC (2)	ECSP024358A (pt)
ES (1)	ES2307613T3 (pt)
HR (2)	HRP20021032B1 (pt)
HU (1)	HUP0301956A3 (pt)
IL (2)	IL152868A0 (pt)
ME (1)	MEP15608A (pt)
MX (1)	MXPA02011524A (pt)
NO (1)	NO327004B1 (pt)
NZ (1)	NZ522768A (pt)
PL (1)	PL358789A1 (pt)
PT (1)	PT1292607E (pt)
RS (1)	RS50493B (pt)
SK (1)	SK2922003A3 (pt)
UA (1)	UA73988C2 (pt)
WO (1)	WO2001090137A2 (pt)
ZA (1)	ZA200209322B (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE10218109A1 (de) *	2002-04-23	2003-11-20	Jenapharm Gmbh	Verfahren zum Herstellen von Kristallen, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen
DE10218107A1 (de) *	2002-04-23	2003-11-20	Jenapharm Gmbh	Verfahren zum Herstellen von Kristallen von Steroiden, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen
EP1838717A2 (en) *	2005-01-18	2007-10-03	Teva Gyógyszergyár Zártköruen Muködo Részvenytarsaság	Amorphous and crystalline forms of dorzolamide hydrochloride and processes of making same
US20090054387A1 (en)	2006-04-18	2009-02-26	Detlef Grawe	Method for preparing 4-[17beta-methoxy-17alpha-methoxymethyl-3-oxestra-4,9-dien-11beta-yl]benzaldehyde (E)-oxime (asoprisnil)
DE102006018888A1 (de) *	2006-04-18	2007-10-25	Bayer Schering Pharma Ag	Verfahren zur Herstellung von 4-[17beta-Methoxy-17alpha-methoxymethyl-3-oxoestra-4,9-dien-11beta-yl]benzaldehyd-(E)-oxims (Asoprisnil)
EP1862468A1 (de) *	2006-06-02	2007-12-05	Bayer Schering Pharma Aktiengesellschaft	Kristallines 11beta-(4-Acetylphenyl)-20,20,21,21,21-pentafluor-17-hydroxy-19-nor-17alpha-pregna-4,9-dien-3-on
DE102009034367A1 (de)	2009-07-20	2011-01-27	Bayer Schering Pharma Aktiengesellschaft	17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzyliden-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102009034362A1 (de)	2009-07-20	2011-01-27	Bayer Schering Pharma Aktiengesellschaft	17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034368A1 (de)	2009-07-20	2011-01-27	Bayer Schering Pharma Aktiengesellschaft	17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylenphenyl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034366A1 (de)	2009-07-20	2011-01-27	Bayer Schering Pharma Aktiengesellschaft	17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-methylenoxyalkylenaryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034525A1 (de)	2009-07-21	2011-01-27	Bayer Schering Pharma Aktiengesellschaft	17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034526A1 (de)	2009-07-21	2011-02-10	Bayer Schering Pharma Aktiengesellschaft	17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-ethinylphenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102010007719A1 (de)	2010-02-10	2011-08-11	Bayer Schering Pharma Aktiengesellschaft, 13353	Progesteronrezeptorantagonisten
DE102010007722A1 (de)	2010-02-10	2011-08-11	Bayer Schering Pharma Aktiengesellschaft, 13353	Progesteronrezeptorantagonisten

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE4332283A1 (de) *	1993-09-20	1995-04-13	Jenapharm Gmbh	Neue 11-Benzaldoximestradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE19610667C2 (de) *	1996-03-08	1998-04-09	Schering Ag	(Z)-11ß-[4-(Dimethylamino)phenyl]17ß-hydroxy-17alpha-(3-hydroxy-1-propenyl)estr-4-en-3-on als kristallines Ansolvat
EP1204656A2 (en) *	1999-07-29	2002-05-15	Eli Lilly And Company	A crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl) ethoxy] phenoxy)-2-(4-methoxyphenyl) benzo[b]thiophene hydrochloride

2000
- 2000-05-23 EP EP00110887A patent/EP1157996A1/de not_active Withdrawn
2001
- 2001-05-09 ES ES01929632T patent/ES2307613T3/es not_active Expired - Lifetime
- 2001-05-09 RS YUP-887/02A patent/RS50493B/sr unknown
- 2001-05-09 US US10/296,463 patent/US7799770B2/en active Active
- 2001-05-09 CZ CZ2003620A patent/CZ2003620A3/cs unknown
- 2001-05-09 SK SK292-2003A patent/SK2922003A3/sk not_active Application Discontinuation
- 2001-05-09 PL PL01358789A patent/PL358789A1/xx not_active IP Right Cessation
- 2001-05-09 EP EP07115136A patent/EP1862469A2/de not_active Withdrawn
- 2001-05-09 NZ NZ522768A patent/NZ522768A/en unknown
- 2001-05-09 DK DK01929632T patent/DK1292607T3/da active
- 2001-05-09 ME MEP-156/08A patent/MEP15608A/xx unknown
- 2001-05-09 PT PT01929632T patent/PT1292607E/pt unknown
- 2001-05-09 CA CA002409869A patent/CA2409869C/en not_active Expired - Lifetime
- 2001-05-09 AU AU2001256344A patent/AU2001256344B2/en not_active Ceased
- 2001-05-09 IL IL15286801A patent/IL152868A0/xx unknown
- 2001-05-09 DE DE50114012T patent/DE50114012D1/de not_active Expired - Lifetime
- 2001-05-09 AT AT01929632T patent/ATE397617T1/de not_active IP Right Cessation
- 2001-05-09 MX MXPA02011524A patent/MXPA02011524A/es active IP Right Grant
- 2001-05-09 WO PCT/EP2001/005237 patent/WO2001090137A2/de active Application Filing
- 2001-05-09 HU HU0301956A patent/HUP0301956A3/hu unknown
- 2001-05-09 EA EA200201192A patent/EA005623B1/ru not_active IP Right Cessation
- 2001-05-09 JP JP2001586324A patent/JP2003534350A/ja active Pending
- 2001-05-09 EP EP01929632A patent/EP1292607B1/de not_active Expired - Lifetime
- 2001-05-09 AU AU5634401A patent/AU5634401A/xx active Pending
- 2001-05-09 BR BR0111058-6A patent/BR0111058A/pt not_active IP Right Cessation
- 2001-05-09 CN CNB018099394A patent/CN100384867C/zh not_active Expired - Fee Related
- 2001-05-09 KR KR1020027015762A patent/KR100553292B1/ko not_active IP Right Cessation
- 2001-09-05 UA UA20021210147A patent/UA73988C2/uk unknown
2002
- 2002-11-14 IL IL152868A patent/IL152868A/en not_active IP Right Cessation
- 2002-11-15 ZA ZA200209322A patent/ZA200209322B/en unknown
- 2002-11-22 NO NO20025613A patent/NO327004B1/no not_active IP Right Cessation
- 2002-11-22 EC EC2002004358A patent/ECSP024358A/es unknown
- 2002-12-23 HR HR20021032A patent/HRP20021032B1/xx not_active IP Right Cessation
2003
- 2003-02-14 BG BG107557A patent/BG65968B1/bg unknown
2008
- 2008-08-29 HR HR20080423A patent/HRP20080423A2/xx not_active Application Discontinuation
- 2008-10-22 EC EC2008004358A patent/ECSP084358A/es unknown

Also Published As

Publication number	Publication date
AU2001256344B8 (en)	2001-12-03
RS50493B (sr)	2010-03-02
NO327004B1 (no)	2009-04-06
CN1430624A (zh)	2003-07-16
CZ2003620A3 (cs)	2003-08-13
ECSP084358A (es)	2008-11-27
EP1292607B1 (de)	2008-06-04
US20040006241A1 (en)	2004-01-08
CA2409869C (en)	2009-02-03
MXPA02011524A (es)	2004-09-10
EP1157996A1 (de)	2001-11-28
CN100384867C (zh)	2008-04-30
HRP20080423A2 (en)	2008-10-31
ECSP024358A (es)	2003-03-31
HRP20021032A2 (en)	2005-02-28
NO20025613D0 (no)	2002-11-22
US7799770B2 (en)	2010-09-21
YU88702A (sh)	2006-01-16
HUP0301956A2 (hu)	2003-09-29
PL358789A1 (en)	2004-08-23
EA005623B1 (ru)	2005-04-28
PT1292607E (pt)	2008-09-15
IL152868A0 (en)	2003-06-24
MEP15608A (en)	2010-06-10
DE50114012D1 (en)	2008-07-17
EP1862469A2 (de)	2007-12-05
NZ522768A (en)	2005-03-24
IL152868A (en)	2009-08-03
NO20025613L (no)	2002-11-22
CA2409869A1 (en)	2002-11-20
JP2003534350A (ja)	2003-11-18
HUP0301956A3 (en)	2010-03-29
BG65968B1 (bg)	2010-07-30
SK2922003A3 (en)	2003-08-05
BR0111058A (pt)	2003-04-15
ES2307613T3 (es)	2008-12-01
DK1292607T3 (da)	2008-10-13
EA200201192A1 (ru)	2003-06-26
ZA200209322B (en)	2005-03-10
KR100553292B1 (ko)	2006-02-22
WO2001090137A3 (de)	2002-04-04
ATE397617T1 (de)	2008-06-15
KR20030028742A (ko)	2003-04-10
AU2001256344B2 (en)	2007-01-25
BG107557A (bg)	2004-01-30
HRP20021032B1 (en)	2008-09-30
EP1292607A2 (de)	2003-03-19
AU5634401A (en)	2001-12-03
WO2001090137A2 (de)	2001-11-29

Publication	Publication Date	Title
UA73988C2 (en)	2005-10-17	SOLID BODY FORMS OF MESOPROGESTIN -11b-[4??-(HYDROXY IMINOMETHYL)-PHENYL]-17a-METHOXY-17b-METHOXY-ESTRA-4,9-DIEN-3-ONE
JP6877389B2 (ja)	2021-05-26	オベチコール酸の調製、使用および固体形態
JP6200977B2 (ja)	2017-09-20	３−（４−アミノ−１−オキソ−１，３ジヒドロ−イソインドール−２−イル）−ピペリジン−２，６−ジオンの多形相
CA2479991C (en)	2010-06-22	Process for production of crystals, crystals obtained thereby and their use in pharmaceutical preparations
Aitipamula et al.	2012	Co-crystals of caffeine and piracetam with 4-hydroxybenzoic acid: Unravelling the hidden hydrates of 1: 1 co-crystals
US7910573B2 (en)	2011-03-22	Crystalline forms of 11β-(4-acetylphenyl)-20,20,21,21,21-pentafluoro-17-hydroxy-19-nor-17α-pregna-4,9-dien-3-one
Park et al.	2005	Use of CP/MAS solid-state NMR for the characterization of solvate molecules within estradiol crystal forms
JP2018538331A (ja)	2018-12-27	オベチコール酸の多型結晶形態
Wang et al.	2016	Solid-state characterization of 17β-estradiol co-crystals presenting improved dissolution and bioavailability
Chen et al.	2022	Pharmaceutical cocrystals of nomegestrol acetate with superior dissolution
JP2021500359A (ja)	2021-01-07	選択的プロゲステロンの受容体モジュレーターの結晶形およびその製造方法
EA045559B1 (ru)	2023-12-05	Кислотно-аддитивные соли селективного антагониста гистаминовых h3-рецепторов и способ их получения
BRPI0710517A2 (pt)	2011-08-16	método para preparar 4-[17 beta-metóxi-17alfa-metoximetil-3-oxoestra-4,9-diean- 11beta-il]benzaldeìdo (e)-oxima (asoprisnil)
CZ2017646A3 (cs)	2019-04-24	Kokrystal (3α,5ß,6α,7α)-6-ethyl-3,7-dihydroxycholan-24-ové kyseliny s kyselinou benzoovou
WO2016113242A1 (en)	2016-07-21	Di-pidotimod benzathine and solid forms thereof
CZ2010227A3 (cs)	2011-10-05	Nové soli (2R)-2-{(1S)-6,7-dimethoxy-1-[2-(4-trifluoromethyl-fenyl)-ethyl]-3,4-dihydro-1H-isochinolin-2-yl}-N-methyl-2-fenyl-acetamidu (almorexantu) a zpusob jejich prípravy
TW201522361A (zh)	2015-06-16	非晶形烏普司他醋酸